Tarik Suljic

Dr. Tarik Suljic

orcid

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 February 2025 in Journal of Clinical Epidemiology
Verified
Journal Article
Open access
GNGustav Nilsonne
Gustav Nilsonne
SWSusanne Wieschowski
Susanne Wieschowski
NDNicholas J. DeVito
Nicholas J. DeVito
MSMaia Salholz-Hillel
Maia Salholz-Hillel
LALove Ahnström
Love Ahnström
CACathrine Axfors
Cathrine Axfors
To systematically evaluate timely reporting of clinical trial results at medical universities and university hospitals in the Nordic countries. In this cross-sectional study, we included trials (regardless of intervention) registered in the European Union (EU) Clinical Trials Registry and/or ClinicalTrials.gov, completed 2016-2019 and led by a university with medical faculty or university hospital in Denmark, Finland, Iceland, Norway, or Sweden. We identified summary results posted at the trial registries and conducted systematic manual searches for results publications (eg, journal articles, preprints). We present proportions with 95% confidence intervals (CI) and medians with interquartile range (IQR). https://osf.io/wua3r. Among 2112 included clinical trials, 1650 (78.1%, 95% CI 76.3%-79.8%) reported any results during our follow-up; 1097 (51.9%, 95% CI 49.8%-54.1%) reported any results within 2 years of the global completion date; and 48 (2.3%, 95% CI 1.7%-3.0%) posted summary results in the registry within 1 year. The median time from global completion date to results reporting was 690 days (IQR 1103). 856/1681 (50.9%) of ClinicalTrials.gov registrations were prospective. Denmark contributed approximately half of all trials. Reporting performance varied widely between institutions. Missing and delayed results reporting of academically led clinical trials are a pervasive problem in the Nordic countries. We relied on trial registry information, which can be incomplete. Institutions, funders, and policymakers need to support trial teams, ensure regulation adherence, and secure trial reporting before results are permanently lost. Reporting of results from clinical trials is necessary for evidence-based clinical decision-making. We followed up reporting of clinical trials in the Nordic countries sponsored by medical universities and university hospitals. Of 2112 studies completed 2016-2019 in two major trials registries, about half reported results in any form within 24 months, and more than one in five did not report results at all. These results show that there is a need for improvement in the reporting of Nordic clinical trials.

15 December 2025 in Biomedicine & Pharmacotherapy
Verified
Journal Article
Open access
TSTarik Suljic
Tarik Suljic
BKBakir Kudic
Bakir Kudic
Belma Pehlivanović KelleBelma Pehlivanović Kelle
Belma Pehlivanović Kelle
AHAida Hamzic-Mehmedbasic
Aida Hamzic-Mehmedbasic
JMJasminka Mujic
Jasminka Mujic
ACAida Kulo Cesic
Aida Kulo Cesic
The burden of nephrotoxicity and ototoxicity consequences caused by gentamicin warrants preventive therapeutic measures. Our aim was to evaluate combined and potentially synergistic effects of rosuvastatin and curcumin, both possessing anti-inflammatory and antioxidant properties, compared to their monotherapies in a gentamicin-induced model of nephrotoxicity and ototoxicity. In a randomized, controlled study, 36 male Wistar rats were allocated to six groups and treated for 5 days: negative control group received solvent, model group gentamicin (100 mg/kg, intraperitoneally), treatment groups gentamicin and via orogastric tube either standard-dose rosuvastatin (5 mg/day), reduced-dose rosuvastatin (1.25 mg/day), curcumin (100 mg/kg), or combination of reduced-dose rosuvastatin and curcumin. Human rosuvastatin doses were converted to rat doses using the conversion factor of 6.2. Functional outcomes evaluated by Preyer pinna reflex for hearing and a vestibular battery test were complemented by renal and cochlear histology, biochemical biomarkers of injury, inflammation, and oxidative stress. Gentamicin induced proximal tubular necrosis and cochlear and vestibular damage. Compared to monotherapies, combination therapy significantly preserved renal architecture, improved renal biomarkers, reduced early inflammatory biomarkers, preserved cochlear architecture and drove vestibular protection. It also alleviated gentamicin-induced cardiotoxicity. Rosuvastatin provided stronger auditory protection, with reduced-dose rosuvastatin superior to standard-dose in preserving vestibular function. Bliss independence modelling showed that combined therapy synergistically inhibited kidney injury and inflammation. In conclusion, the combination of reduced-dose rosuvastatin and curcumin outperforms both monotherapies in alleviating gentamicin-induced nephrotoxicity, audiotoxicity and vestibulotoxicity, whilst synergistically attenuating nephrotoxicity and early-phase inflammation in rats. These findings highlight promising preventive strategies against aminoglycoside nephrotoxicity and ototoxicity.

18 August 2026 in Future Pharmacology
Verified
Journal Article
Open access
PDF file
Belma Pehlivanović KelleBelma Pehlivanović Kelle
Belma Pehlivanović Kelle
DLDina Lagumdzija
Dina Lagumdzija
TSTarik Suljic
Tarik Suljic
AHAida Hamzic-Mehmedbasic
Aida Hamzic-Mehmedbasic
JKJasna Kusturica
Jasna Kusturica
ACAida Kulo Cesic
Aida Kulo Cesic
Background: Rosuvastatin, a potent lipid-lowering statin, and curcumin, a bioactive naturally occurring polyphenolic phytochemical, both show pleiotropic antioxidant and anti-inflammatory properties. In addition, curcumin shows also antimicrobial, anticancer, hypolipidemic and antifibrotic effects. From the pharmacodynamic point, rosuvastatin and curcumin target overlapping molecular pathways—suggesting possible pharmacodynamic synergy that has emerged as a promising therapeutic approach in the management of various diseases, including cardiovascular, metabolic, kidney, and inflammatory diseases. Objectives: This review aimed to systematically summarize and critically evaluate all available preclinical data concerning the combined use of rosuvastatin and curcumin, emphasizing their possible synergistic effects. Methods: A total of seven preclinical studies that investigated the combination of curcumin and rosuvastatin, three in vitro and four in vivo, conducted between 2017 and 2025, were included in the analysis. Results: While in vitro studies suggested a promising synergy in lipid-lowering, antioxidant, and anti-inflammatory effects, in vivo findings confirmed enhanced lipid-lowering effects, potential hepatoprotection and nephroprotection when two agents are co-administered. In addition to pharmacodynamic interaction, pharmacokinetic studies also revealed that curcumin may increase systemic rosuvastatin exposure by inhibiting hepatic transporters, warranting further investigation into dosing and safety of the combination. Conclusions: While current evidence supports the therapeutic potential of the combined use of rosuvastatin and curcumin, additional pharmacokinetic, mechanistic, and clinical studies are needed to fully assess its translational value.

5 February 2024 in medRxiv
Verified
Preprint
Open access
PDF file
GNGustav Nilsonne
Gustav Nilsonne
SWSusanne Wieschowski
Susanne Wieschowski
NDNicholas J. DeVito
Nicholas J. DeVito
MSMaia Salholz-Hillel
Maia Salholz-Hillel
LALove Ahnström
Love Ahnström
CACathrine Axfors
Cathrine Axfors
Objective To systematically evaluate timely reporting of clinical trial results at medical universities and university hospitals in the Nordic countries. Study Design and Setting In this cross-sectional study, we included trials (regardless of intervention) registered in the EU Clinical Trials Registry and/or ClinicalTrials.gov, completed 2016-2019, and led by a university with medical faculty or university hospital in Denmark, Finland, Iceland, Norway, or Sweden. We identified summary results posted at the trial registries, and conducted systematic manual searches for results publications (e.g., journal articles, preprints). We present proportions with 95% confidence intervals (CI), and medians with interquartile range (IQR). Protocol: https://osf.io/wua3r Results Among 2,113 included clinical trials, 1,638 (77.5%, 95%CI 75.9-79.2%) reported any results during our follow-up; 1,092 (51.7%, 95%CI 49.5-53.8%) reported any results within 2 years of the global completion date; and 42 (2%, 95%CI 1.5-2.7%) posted summary results in the registry within 1 year. Median time from global completion date to results reporting was 698 days (IQR 1,123). 856/1,681 (50.9%) of ClinicalTrials.gov-registrations were prospective. Denmark contributed approximately half of all trials. Reporting performance varied widely between institutions. Conclusion Missing and delayed results reporting of academically-led clinical trials is a pervasive problem in the Nordic countries. We relied on trial registry information, which can be incomplete. Institutions, funders, and policy makers need to support trial teams, ensure regulation adherence, and secure trial reporting before results are permanently lost. What is new? - Many Nordic registered clinical trials were reported late or not at all. - Almost one in four trials remained unreported at the end of our search period. - About half of registered trials had reported results two years after completion. - Only 2% of trials posted summary results in the registry one year after completion. - Concerted action is needed to improve reporting of Nordic clinical trials.

6 April 2023 in medRxiv
Verified
Preprint
Open access
PDF file
MOMarguerite O’riordan
Marguerite O’riordan
MHMartin Haslberger
Martin Haslberger
CCCarolina Cruz
Carolina Cruz
TSTarik Suljic
Tarik Suljic
MRMartin Ringsten
Martin Ringsten
TBTill Bruckner
Till Bruckner
Objectives Assess the extent to which the clinical trial registration and reporting policies of 25 of the world’s largest public and philanthropic medical research funders meet best practice benchmarks as stipulated by the 2017 WHO Joint Statement,(1) and document changes in the policies and monitoring systems of 19 European funders over the past year. Design, Setting, Participants Cross sectional study, based on assessments of each funder’s publicly available documentation plus validation of results by funders. Our cohort includes the 25 of the largest public and philanthropic medical research funders in Europe, Oceania, South Asia and Canada. Of these, 19 were previously assessed against the same benchmarks, enabling us to document changes over time. Interventions Scoring of all 25 funders using an 11-item assessment tool based on WHO best practice benchmarks, grouped into 3 primary categories: trial registries, academic publication and monitoring, plus validation of results by funders. Main outcome measures The primary outcome measure is how many of the 11 WHO best practice items each of the 25 funders has put into place, and changes in the performance of 19 previously assessed funders over the preceding year. Results The 25 funders we assessed had put into place an average of 5/11 (49%) WHO best practices. The best practice adopted by most funders 16/25 (64%) was mandating open access publication in journals. In contrast, only 6/25 funders (24%) took PI’s past reporting record into account during grant application reviews. Funders’ performance varied widely from 0/11 to 11/11 WHO best practices adopted. Of the 19 funders for which 2021 baseline data were available,(2) 10/19 (53%) had strengthened their policies over the preceding year. Conclusions Most medical research funders need to do more to curb research waste and publication bias by strengthening their clinical trial policies. Key Points WHAT IS ALREADY KNOWN ABOUT THIS TOPIC Key PointsStrong clinical trial registration and reporting policies coupled with monitoring and sanctions can reduce research waste, curb publication bias and promote transparency. A 2021 assessment found that 19 European medical research funders’ policies fell short of WHO best practices. WHAT THIS STUDY ADDS This is the first study to assess the clinical trial registration and reporting policies of a global cohort of 25 major medical research funders against WHO best practices, identifying gaps in the research waste safeguards of key players across Europe, Oceania, South Asia and Canada. In addition, the study assesses the progress made by 19 funders in the recent past. HOW THIS STUDY MIGHT AFFECT RESEARCH, PRACTICE OR POLICY This study enables funders worldwide to identify and address gaps in their clinical trial transparency policies by pinpointing exactly where they currently fall short of WHO best practices. It also enables policy makers and citizens to assess whether public bodies tasked with furthering medical knowledge have adopted adequate safeguards against research waste and publication bias.

31 October 2024 in Biomolecules and Biomedicine
Verified
Journal Article
Open access
PDF file
AČAdisa Čengić
Adisa Čengić
SHSniježana Hasanbegović
Sniježana Hasanbegović
IHIzeta Hamza
Izeta Hamza
TSTarik Suljic
Tarik Suljic
VSVelma Selmanović
Velma Selmanović
NDNejra Džananović
Nejra Džananović
Juvenile idiopathic arthritis (JIA) is the most common chronic inflammatory autoimmune disease in childhood, significantly contributing to both short- and long-term disability. While certain human leukocyte antigen (HLA) class II alleles are known to be associated with specific subgroups of JIA, emerging evidence suggests a strong correlation between these alleles and treatment response. This study involved 143 JIA patients diagnosed according to International League of Associations for Rheumatology criteria. Each patient underwent HLA class II typing, including HLA-B27, as well as tests for rheumatoid factor (RF) and antinuclear antibodies (ANA). Comprehensive rheumatological assessments were conducted at diagnosis, with follow-ups at three and six months post-onset. After six months of methotrexate (MTX) treatment, patients were categorized as responders or non-responders. Responders achieved clinically inactive disease based on the American College of Rheumatology Provisional Criteria for Defining Clinical Inactive Disease and Clinical Remission. Non-responders, who did not reach clinically inactive disease after six months of treatment, required the addition of another non-biological disease-modifying antirheumatic drug (DMARD) or a biological DMARD. Our analysis revealed that the HLA-DRB1*01 allele is a significant prognostic marker for therapeutic response, predicting therapeutic resistance (P=0.01). The most prevalent HLA-DRB1 alleles in the treatment-resistant group were HLA-DRB1*08:11 (11.3%), HLA-DRB1*01:01 (8.5%), HLA-DRB1*01:13, HLA-DRB1*04:11 (7%), HLA-DRB1*08:13, and HLA-DRB1*08:15 (4.2%). These findings highlight the critical role of HLA class II alleles in pediatric rheumatology, particularly in relation to treatment response and disease prognosis. In the era of personalized medicine, understanding the genetic contributions to treatment response and outcomes in JIA patients is essential. A key limitation of this study was the lack of comparison of treatment responses across different JIA subtypes. Future studies should prioritize evaluating MTX efficacy within specific JIA subgroups to enable a more tailored understanding of its effectiveness.